Mahlangu J.
University of the Witwatersrand
South Africa
About
No AI summary yet.
Metrics
- Publications
- 273
- Citations
- 12.1K
- h-index
- 44
- Publishing journals
- 77
- Years of publications
- 20+
- Active since
- 2007
- References
- 7.4K
- Institutions
- 11
Publication history
Latest publications
- Concizumab in hemophilia with inhibitors: Longer-term efficacy and safety results from the phase 3 explorer7 study.
- The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025.
- Futuristic global cell and gene therapy regulations based on a review of today's leading frameworks.
- Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.
- A comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and Summary of Product Characteristics (SMPCs); Communication from the ISTH SSC Working Group on Gene Therapy.
- Is marstacimab the next step in personalized and effective haemophilia management?
- A Revised Classification of FVIII Concentrates: Rationale and Novel Metrics.
- Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B
- Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial.
- Concizumab, a Non-Replacement Therapy for Persons with Hemophilia with Inhibitors.
- Efficacy and Safety of rVIII‐SingleChain in Surgical Prophylaxis
- Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice.
- Adeno-associated virus-based gene therapy for hemophilia–addressing the gaps
- Could Lentivirus Overcome the AAV Gene-Therapy Challenges in Hemophilia A?
- Marstacimab for the Treatment of Hemophilia A or B
- Corrigendum to ‘FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic’: [Journal of Thrombosis and Haemostasis Volume 22, Issue 4, April 2024, Pages 990-1000] (Journal of Thrombosis and Haemostasis (2024) 22(4) (990–1000), (S1538783623009145), (10.1016/j.jtha.2023.12.016))
- FRONTIER1 multiple ascending dose extension: a safety, tolerability, pharmacokinetics, and pharmacodynamics study of Mim8 in people with hemophilia A.
- The impact of Iso-mukaadial acetate on Plasmodium falciparum transcriptional gene regulation
- Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience
- A Phase 1b, Open-label, Multiple-Dose Study Evaluating Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Pociredir in Patients With Sickle Cell Disease (SCD): Trial Design
No publications in the index yet.